Regulatory Risks Will Hinder Ophthalmology Trials Yet Future Upside Emerges

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

AnalystLowTarget

Not Invested

Community Contributor

Published

07 Aug 25

n/a

AnalystLowTarget's Fair Value

n/a

-1.2%

-5.8%

-1.2%

-5.8%

You can edit this narrative until Aug 7 10:47 PM. Then, changes will post as Updates.

Author's Valuation

US$1422.8% undervalued

AnalystLowTarget Fair Value

Narrative

Updates0